EMA Authorised: Sycrest (asenapine maleate) — Organon N.V.

View source ↗

Summary

The EMA authorised Sycrest (asenapine maleate) for the treatment of bipolar disorder. Organon N.V. is the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• Sycrest (asenapine maleate)

Snippet

Status: Authorised. Therapeutic area: Bipolar Disorder. MAH: Organon N.V.. Decision date: 25/02/2026